-
Astellas Pharma Appoints Zhao Ping as Chairman of China Operations
•
Effective January 15, 2024, Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has appointed Zhao Ping as the chairman of its China operations. This strategic appointment comes as the company looks to strengthen its presence and leadership in the Chinese market. Zhao Ping brings a wealth of experience to…
-
Keylights Biotechnology Raises $14 Million in Series B to Expand IVD Instrument Range
•
Keylights Biotechnology Co., Ltd., a leading in vitro diagnostic (IVD) instruments manufacturer headquartered in Shenzhen, has reportedly secured nearly RMB 100 million (USD 14 million) in a Series B financing round. The round was led by Luxin Venture Capital, with participation from Hanchi Venture Capital. The funds raised will be…
-
Joincare Pharmaceutical’s Partner Fermion Gets NMPA Green Light for Pain Drug Clinical Study
•
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced that Fermion’s FZ008-145 has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for pain treatment in China. Fermion, which previously granted Joincare exclusive rights to the drug in Greater…
-
Gansu Deshengtang Partners with RELEX Solutions to Enhance Supply Chain Efficiency
•
Gansu Deshengtang Medical Science and Technology Group Co., Ltd, a prominent Chinese healthcare group, has entered into a strategic partnership with Finland-based retail technology platform RELEX Solutions. Through the adoption of RELEX’s advanced forecasting and replenishment solutions, Deshengtang aims to optimize its end-to-end supply chain operations, rectify inventory structures, and…
-
GSK Secures Second Indication Approval for Nucala in China for Severe Eosinophilic Asthma
•
GSK plc (NYSE: GSK) has received approval for a second indication in China for its anti-interleukin-15 (IL-15) biologic, Nucala (mepolizumab). The drug is now authorized as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older. Nucala was initially approved in China in…
-
China Resources Medical Laboratory Partners with Qlife Lab for Comprehensive Mass Spectrometry Solutions
•
China Resources Medical Holdings Company Limited’s subsidiary, China Resources (Guangdong) Medical Laboratory Co., Ltd, has entered into a partnership with fellow Chinese firm Qlife Lab to deliver comprehensive mass spectrometry solutions to medical institutions. The collaboration aims to provide a one-stop service for mass spectrometry, enhancing the capabilities of medical…
-
WuXi Biologics Partners with BioNTech to Develop Next-Gen Antibodies in $20 Million Deal
•
WuXi Biologics (HKG: 2269), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has entered into a research service agreement with Germany’s BioNTech (NASDAQ: BNTX). As part of the collaboration, WuXi Bio will leverage its patented technology platform to develop antibodies targeting two undisclosed targets for BioNTech, aimed at advancing…
-
Junshi Biosciences Regains Global Rights to JS006 as Coherus Terminates Licensing Agreement
•
Junshi Biosciences (HKG: 1877; SHA: 688180), based in Suzhou, has announced the termination of its licensing agreement with US-based Coherus BioSciences Inc. (NASDAQ: CHRS) concerning the T cell immunoglobulin and ITIM domains (TIGIT) monoclonal antibody CHS-006/JS006. The original licensing deal, established in February 2021, granted Coherus exclusive rights to Junshi’s…
